Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia.

Biomolecules - 23 Sept 2022

Gao Yan, Zhou Jia-Fan, Mao Jia-Ying, Jiang Lu, Li Xue-Ping

Abstract excerpt

Acute myeloid leukemia (AML) is a biologically and genetically heterogeneous hematological malignance with an unsatisfactory risk stratification system. Recently, through the novel single-cell RNA sequencing technology, we revealed heterogeneous leukemia myeloblasts in RUNX1-RUNX1T1 AML. Thyrotropin-releasing hormone (TRH), as biomarkers of CD34+CD117bri myeloblasts, were found to be prognostic in RUNX1-RUNX1T1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nuclear Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36291567
DOI: 10.3390/biom12101359
PMCID: PMC9599642

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia.PMID 36291567Read ↗

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaSemantic proximity Read ↗

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.Semantic proximity Read ↗

High expression of TARP correlates with inferior FLT3 mutations in non-adolescents and young adults with acute myeloid leukaemia.Semantic proximity Read ↗

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.Semantic proximity Read ↗

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemiaSemantic proximity Read ↗

The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implicationsSemantic proximity Read ↗

Runx1 Gene in Acute Myeloid Leukemia: Expression Level Significance and Impact on Clinical FeaturesSemantic proximity Read ↗

Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.